Immunology and Bi...
Follow
Find
5.4K views | +0 today
 
Scooped by Gilbert Faure au nom de l'ASSIM from Institut Pasteur de Tunis-معهد باستور تونس
onto Immunology and Biotherapies
Scoop.it!

Medical History

Medical History | Immunology and Biotherapies | Scoop.it

Via Seth Dixon, Institut Pasteur de Tunis - معهد باستور تونس‎
Gilbert Faure au nom de l'ASSIM's insight:

but nowadays, researchers spend much time to get money to work.... and to learn and on the other hand, biotherapies market is skyrocketting!

more...
Seth Dixon's curator insight, December 13, 2013 11:31 AM

I found this on social media (unfortunately I don't have an original source to link to fo documentation) and was greatly impressed by the information here, but also the historical implications of this information.  Could/would this happen today?  How would the world be different is this was the 'new normal?'  How would the world be different if this never did happen?

From around the web

Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation - The Journal of Heart and Lung Transplantation

Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation http://t.co/4L1jQL4PBs #CancerNews
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novel Therapeutic Approach for Neurogenic Erectile Dysfunction: Effect of Neurotrophic Tyrosine Kinase Receptor Type 1 Monoclonal Antibody - European Urology

Novel Therapeutic Approach for Neurogenic Erectile Dysfunction: Effect of Neurotrophic Tyrosine Kinase Receptor Type 1 Monoclonal Antibody - European Urology | Immunology and Biotherapies | Scoop.it
European Urology, the official journal of the EAU, has been a prestigious urological forum for over 35 years, and is currently read by more than 20,000 urologists across the globe.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stem-cell replication to treat blood diseases - CMAJ

Stem-cell replication to treat blood diseases - CMAJ | Immunology and Biotherapies | Scoop.it
Stem-cell replication to treat blood diseases
CMAJ
Human clinical trials are set to start in December to test an innovative approach to treating life-threatening blood diseases, such as leukemia.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Activation and Propagation of Tumor-infiltrating Lymphocytes... : Journal of Immunotherapy

Activation and Propagation of Tumor-infiltrating Lymphocytes... : Journal of Immunotherapy | Immunology and Biotherapies | Scoop.it
Purpose:Adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL) is a therapy for metastatic melanoma with response rates of up to 50%.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Useful insights: Europe slow to embrace biosimilars of antibody-based drugs - BioPharma Dive

Useful insights: Europe slow to embrace biosimilars of antibody-based drugs - BioPharma Dive | Immunology and Biotherapies | Scoop.it
After the EMA approved Hospira's Inflectra—a biosimilar of J&J's Remicade (infliximab)—Hospira launched an intensive marketing campaign. Here's an overview of what's happened since then.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Potential use of [gammadelta] T cell-based vaccines in cancer immunotherapy | T Cell Biology

Immunotherapy is a fast advancing methodology involving one of two approaches: 1) compounds targeting immune checkpoints, and 2) cellular immunomodulators. The latter approach is still largely expe...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Biosimilars Set to Revolutionize Global Drug Development

Biosimilars Set to Revolutionize Global Drug Development | Immunology and Biotherapies | Scoop.it
Biosimilars are expected to account for approximately 1/4 of the $100 billion worth of sales stemming from off-patent biologics by the end of the decade.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Seizing the Future in Oncology: Improving the Clinical Development of ... - DigitalJournal.com

TORONTO, ON--(Marketwired - October 15, 2014) - This webinar will discuss key considerations in the development of immuno-oncology therapeutics.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis | Immunology and Biotherapies | Scoop.it
Therapeutic uses of anti-{alpha}4-integrin (anti-VLA-4) antibodies in multiple sclerosis http://t.co/gO0pYsupA8
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Differential Efficacy of Human Mesenchymal Stem Cells Based on Source of Origin [AUTOIMMUNITY]

Mesenchymal stem cells (MSCs) are useful in tissue repair but also possess immunomodulatory properties. Murine and uncontrolled human trials suggest efficacy of MSCs in treating lupus.
Gilbert Faure au nom de l'ASSIM's insight:

..... Autologous cells are preferable; however, recent studies suggest that lupus-derived MSCs lack efficacy in treating disease. Thus, the optimum derivation of MSCs for use in lupus is unknown. It is also unknown which in vitro assays of MSC function predict in vivo efficacy. The objectives for this study were to provide insight into the optimum source of MSCs and to identify in vitro assays that predict in vivo efficacy. We derived MSCs from four umbilical cords, four healthy bone marrows (BMs), and four lupus BMs. In diseased MRL/lpr mice, MSCs from healthy BM and umbilical cords significantly decreased renal disease, whereas lupus BM MSCs only delayed disease. Current in vitro assays did not differentiate efficacy of the different MSCs. However, differences in MSC efficacy were observed in B cell proliferation assays.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity

GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity - up-to-the-minute news and headlines.
Gilbert Faure au nom de l'ASSIM's insight:

Methods: Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Cancer immunotherapy using a potent immunodominant CTL epitope

Cancer immunotherapy using a potent immunodominant CTL epitope | Immunology and Biotherapies | Scoop.it

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

Here, we investigated whether intratumoral injection of a foreign immunodominant peptide (GP33) and the adjuvant CpG into tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and GP33 was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and GP33 also enhanced the generation of GP33-specific and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci, a process found to be mediated by the Fas–FasL apoptosis pathway. The treatment regimen presented here represents a universal approach to cancer control.

more...
Krishan Maggon 's curator insight, October 19, 7:06 AM
Vaccine

Volume 32, Issue 46, 21 October 2014, Pages 6039–6048

 Cancer immunotherapy using a potent immunodominant CTL epitopeLiwen Songa, b, c, d, Ming-Chieh Yangh, Jayne Knoffd, Zu-Yue Sunc, T.-C. Wud, e, f, g, Chien-Fu Hungd, g, , , DOI: 10.1016/j.vaccine.2014.09.021
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

The role of phage display in therapeutic antibody discovery

The role of phage display in therapeutic antibody discovery | Immunology and Biotherapies | Scoop.it
RT @Immunology_News: The role of phage display in therapeutic antibody discovery http://t.co/ed6UpBD9yM
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Effect of Antigen Shedding on Targeted Delivery of ... [PLoS One. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Lilly, Zymeworks Expand Bi-Specific Antibodies Collaboration to $375M - Genetic Engineering & Biotechnology News

Lilly, Zymeworks Expand Bi-Specific Antibodies Collaboration to $375M - Genetic Engineering & Biotechnology News | Immunology and Biotherapies | Scoop.it
Lilly will make an initial upfront payment in the form of an equity investment of undisclosed value.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Dendritic Cell Vaccine First Promising Innovative Medicine

Dendritic Cell Vaccine First Promising Innovative Medicine | Immunology and Biotherapies | Scoop.it
The Promising Innovative Medicine is part of the Early Access to Medicines Scheme (EAMS) to accelerate the availability of medicines for ‘serious diseases.’
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Cytokine therapy reverses NK cell anergy in MH... [J Clin Invest. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Baxter Launches HYQVIA in the United States for Adult Patients with Primary ... - DigitalJournal.com

DEERFIELD, Ill.--(Business Wire)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc.,
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy

Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy | Immunology and Biotherapies | Scoop.it
New Journal of Science is a peer-reviewed, open access journal covering a wide range of subjects in the life sciences. The journal's Editorial Board is divided into the 13 subject areas included within the journal's scope.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Development of NK cell expansion methods using fee... [Blood Res. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Medigene announces publication in Cancer Immunology, Immunotherapy on DC ... - NASDAQ

Medigene announces publication in Cancer Immunology, Immunotherapy on DC ... - NASDAQ | Immunology and Biotherapies | Scoop.it
Medigene AG / Medigene announces publication in Cancer Immunology, Immunotherapy on DC vaccine development for a Phase I/II trial in acute myeloid.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Cell line profiling to improve monoclonal antibody production. [Biotechnol Bioeng. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Gilbert Faure au nom de l'ASSIM's insight:
Abstract

Mammalian cell culture performance is influenced by both intrinsic (genetic) and extrinsic (media and process) factors. In this study, intrinsic capacity of various monoclonal antibody-producing Chinese Hamster Ovary (CHO) cell lines was compared by exposing them to the same culture condition. Microarray-based transcriptomics and LC-MS/MS shotgun proteomics technologies were utilized to obtain expression landscape of different cell lines. Specific transcripts and proteins correlating with productivity, growth rate and cell size have been identified.....

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Vaccine development: NKT-cell adjuvants in conjugate - Nature.com

Vaccine development: NKT-cell adjuvants in conjugate Nature.com Two new studies develop natural killer T (NKT)-cell adjuvants covalently coupled to vaccine epitopes and show that they are useful in generating immune responses to both carbohydrates...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond | Immunology and Biotherapies | Scoop.it
Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient’s own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.
Gilbert Faure au nom de l'ASSIM's insight:

.....

Clinical trials of CAR T cells directed to the CD19 antigen have shown impressive results in advanced B-cell malignancies at multiple academic centers over the last 3 years. We describe the technology of CAR T cells, findings at 5 academic centers, and toxicities associated with CAR T cell-treatment and their management. Although CAR T cells for B-cell malignancies are the most advanced in terms of clinical testing, CAR T cells are the basis of a new platform technology that is poised to be expanded to other hematologic and nonhematologic malignancies, especially as new targets are identified and manufacturing processes are streamlined.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Attacking Angiogenesis Anew: Novel Agents and Strategies Keep Focus on ... - OncLive

Attacking Angiogenesis Anew: Novel Agents and Strategies Keep Focus on ... - OncLive | Immunology and Biotherapies | Scoop.it
A decade after bevacizumab (Avastin) debuted as the first anticancer therapy to target angiogenesis, new strategies to attack this hallmark of cancer continue to be a major research focus, resulting in the development of novel agents and fresh...
Gilbert Faure au nom de l'ASSIM's insight:

Earlier this year, the FDA approved ramucirumab (Cyramza) for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma that progresses after prior therapies. Additional expansion in this field has come from new indications for previously approved agents, including bevacizumab, and several novel agents hold particular promise as treatments for gynecologic malignancies and non–small cell lung cancer (NSCLC).

Yet despite these advances, researchers are far from reaching a complete understanding of the intricacies of tumor vasculature, and significant barriers prevent antiangiogenic therapy from reaching its full potential.

more...
No comment yet.